Upstate Active Clinical Trials
Study Title:ADCS/Biohaven BHV4157-203: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial
to Evaluate the Efficacy and Safety of BHV-4157 in Patients
with Mild to Moderate Alzheimer’s Disease (T2 PROTECT AD)
What is the purpose of the study?The purpose of this study is to test the safety, effectiveness and tolerability of the drug BHV-4157 in patients with Alzheimer's disease.
Upstate Institutional Review Board (IRB) Number:1374750
Study Phase:Phase 2
Patient Age Group:Adults
Principal Investigator:Sharon A Brangman
What is involved if I participate?
- How long is the study?
Where will the study take place?The Clinical Research Unit, located at the Institute for Human Performance (IHP)
Other Information:Subjects are compensated for their time to participate in the study ($40 per completed visit).
Who can I contact for more information?
Name: Colleen A Dillenbeck